Solid Biosciences SLDB
NASDAQ SLDB
$7.16 +0.14 (+1.99%)
As of: Nov 10, 2026 · 3:30 PM EST

Solid Biosciences (SLDB) Receivables (2021)

Updated

Solid Biosciences' Receivables came in at $220,000 for Q4 2021.

Analysis

Solid Biosciences (SLDB) Receivables (2021) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,264.65 Bn 1,238.27 Bn 20.46 Bn 25.23 Bn
2 Johnson & Johnson 677.74 Bn 597.60 Bn 17.30 Bn 18.99 Bn
3 AbbVie 517.10 Bn 485.11 Bn 13.12 Bn 13.51 Bn
4 Merck 362.23 Bn 325.17 Bn 13.19 Bn 12.74 Bn
5 Novartis Ag 315.90 Bn 276.16 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 289.40 Bn 266.24 Bn 12.86 Bn 14.33 Bn
7 Amgen 249.90 Bn 201.56 Bn 7.58 Bn 10.35 Bn
8 Gilead Sciences 209.15 Bn 184.26 Bn 6.73 Bn 5.01 Bn
9 Pfizer 165.88 Bn 113.23 Bn 12.56 Bn 14.19 Bn
10 Solid Biosciences 1.08 Bn -216.77 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2021 220,000.00
API Access

Solid Biosciences Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=SLDB&period=max&api_key=YOUR_API_KEY